BAKER BROS. ADVISORS LP Q2 2016 Filing
Filed August 15, 2016
Portfolio Value
$9.5B
Holdings
135
Report Date
Q2 2016
Filing Type
13F-HR
All Holdings (135 positions)
| # | Stock | Shares | Value | % Portfolio | Type |
|---|---|---|---|---|---|
| 1 | INCYIncyte Corporation | 23,498,697 | $1.9T | 19704.78% | |
| 2 | SGENEURSeattle Genetics, Inc. | 43,238,967 | $1.7T | 18319.38% | |
| 3 | ABBVAbbVie Inc. | 14,373,538 | $889.9B | 9329.77% | |
| 4 | ACADACADIA Pharmaceuticals Inc. | 24,516,738 | $795.8B | 8343.68% | |
| 5 | ALXNAlexion Pharmaceuticals, Inc. | 6,543,295 | $764.0B | 8010.08% | |
| 6 | —Incyte Corporation Notes 1.25% 11/15/2020 144A | 274,500,000 | $467.3B | 4899.32% | |
| 7 | —Incyte Corporation Notes 0.375% 11/15/2018 144A | 259,000,000 | $431.8B | 4527.56% | |
| 8 | BMRNBioMarin Pharmaceutical Inc. | 4,806,483 | $373.9B | 3920.60% | |
| 9 | —Genomic Health, Inc. | 13,668,866 | $354.0B | 3711.03% | |
| 10 | —DBV Technologies S.A. | 5,509,560 | $179.7B | 1884.29% | |
| 11 | —XenoPort, Inc. Notes 2.5% 2/1/2022 | 100,000,000 | $98.5B | 1032.42% | |
| 12 | —Acorda Therapeutics, Inc. | 3,661,082 | $93.4B | 979.00% | |
| 13 | —BioMarin Pharmaceutical Inc. Notes 1.875% 4/23/2017 | 22,379,000 | $84.9B | 890.22% | |
| 14 | CERSCerus Corporation | 13,553,275 | $84.6B | 886.69% | |
| 15 | —Spark Therapeutics, Inc. | 1,318,341 | $67.4B | 706.73% | |
| 16 | —Acorda Therapeutics, Inc. Notes 1.75% 6/15/2021 | 77,083,000 | $67.4B | 706.14% | |
| 17 | —Bellicum Pharmaceuticals, Inc. | 4,865,647 | $63.1B | 661.14% | |
| 18 | ONCBeiGene, Ltd. | 1,912,680 | $57.0B | 597.59% | |
| 19 | HRTXHeron Therapeutics, Inc. | 2,857,250 | $51.6B | 540.72% | |
| 20 | —Aquinox Pharmaceuticals, Inc. | 7,752,487 | $51.3B | 538.07% | |
| 21 | —Clovis Oncology, Inc. 2.5% 9/15/2021 | 72,758,000 | $51.3B | 537.96% | |
| 22 | NVTA1EURInvitae Corporation | 6,554,967 | $48.4B | 507.88% | |
| 23 | BCRXBioCryst Pharmaceuticals, Inc. | 15,010,534 | $42.6B | 446.95% | |
| 24 | NBIXNeurocrine Biosciences, Inc. | 895,422 | $40.7B | 426.69% | |
| 25 | —Versartis, Inc. | 2,723,399 | $30.1B | 315.80% | |
| 26 | —Exelixis, Inc. Notes 4.25% 8/15/2019 | 20,000,000 | $29.7B | 310.91% | |
| 27 | —Advanced Accelerator Applications S.A. | 833,089 | $25.2B | 264.08% | |
| 28 | —XenoPort, Inc. | 3,475,672 | $24.5B | 256.54% | |
| 29 | ITCIEURIntra-Cellular Therapies, Inc. | 609,166 | $23.6B | 247.94% | |
| 30 | GBYSangamo BioSciences, Inc. | 4,055,876 | $23.5B | 246.22% | |
| 31 | NTLAIntellia Therapeutics, Inc. | 1,062,120 | $22.7B | 237.75% | |
| 32 | EX9Exelixis, Inc. | 2,580,000 | $20.1B | 211.26% | |
| 33 | —Medivation, Inc. | 329,876 | $19.9B | 208.56% | |
| 34 | —Achillion Pharmaceuticals, Inc. | 2,475,515 | $19.3B | 202.44% | |
| 35 | NVAXNovavax, Inc. | 2,379,254 | $17.3B | 181.35% | |
| 36 | —Progenics Pharmaceuticals, Inc. | 3,970,250 | $16.8B | 175.66% | |
| 37 | XNCRXencor, Inc. | 872,072 | $16.6B | 173.63% | |
| 38 | HALOHalozyme Therapeutics, Inc. | 1,838,057 | $15.9B | 166.30% | |
| 39 | ARRYEURArray BioPharma Inc. | 4,310,666 | $15.3B | 160.89% | |
| 40 | —Corsicanto Ltd. 3.5% 1/15/2032 | 15,000,000 | $15.3B | 160.26% | |
| 41 | —Aegerion Pharmaceuticals, Inc. Notes 2.0% 8/15/2019 | 26,517,000 | $14.8B | 155.59% | |
| 42 | IM8NInsmed Incorporated | 1,500,000 | $14.8B | 155.07% | |
| 43 | —Derma Sciences, Inc. | 3,752,390 | $14.8B | 155.00% | |
| 44 | GLPGGalapagos NV | 259,894 | $14.4B | 151.14% | |
| 45 | —Foamix Pharmaceuticals Ltd. | 2,241,702 | $14.2B | 149.25% | |
| 46 | —BioMarin Pharmaceutical Inc. Notes 0.75% 10/15/2018 | 12,228,000 | $13.6B | 142.31% | |
| 47 | —bluebird bio, Inc. | 293,943 | $12.7B | 133.41% | |
| 48 | MRTXEURMirati Therapeutics, Inc. | 2,269,198 | $12.4B | 129.90% | |
| 49 | TGTXTG Therapeutics, Inc. | 2,003,991 | $12.1B | 127.32% | |
| 50 | ALKSAlkermes plc | 250,251 | $10.8B | 113.40% | |
| 51 | —Idera Pharmaceuticals, Inc. | 7,000,977 | $10.7B | 112.30% | |
| 52 | —Alcobra Ltd. | 2,336,359 | $10.5B | 109.98% | |
| 53 | ASNDAscendis Pharma A/S | 745,521 | $9.9B | 103.72% | |
| 54 | MGNXMacroGenics, Inc. | 363,676 | $9.8B | 102.92% | |
| 55 | —Dermira, Inc. | 326,428 | $9.5B | 100.11% | |
| 56 | IMGNEURImmunoGen, Inc. | 3,015,353 | $9.3B | 97.37% | |
| 57 | MRUSMerus N.V. | 1,122,859 | $9.0B | 94.07% | |
| 58 | LGNDLigand Pharmaceuticals Incorporated | 73,386 | $8.8B | 91.77% | |
| 59 | AGIOAgios Pharmaceuticals, Inc. | 207,915 | $8.7B | 91.33% | |
| 60 | —Zogenix, Inc. | 1,000,000 | $8.1B | 84.40% | |
| 61 | —Dimension Therapeutics, Inc. | 1,251,881 | $7.5B | 78.75% | |
| 62 | —Aimmune Therapeutics, Inc. | 673,908 | $7.3B | 76.45% | |
| 63 | —Vitae Pharmaceuticals, Inc. | 637,597 | $6.9B | 72.13% | |
| 64 | SG7Sage Therapeutics, Inc. | 224,048 | $6.8B | 70.78% | |
| 65 | —Akari Therapeutics plc | 496,901 | $6.7B | 70.28% | |
| 66 | PRQRProQR Therapeutics N.V. | 1,234,095 | $6.0B | 62.62% | |
| 67 | NTRANatera, Inc. | 450,000 | $5.4B | 56.92% | |
| 68 | —Alder BioPharmaceuticals, Inc. | 217,328 | $5.4B | 56.90% | |
| 69 | RAREUltragenyx Pharmaceutical Inc. | 110,894 | $5.4B | 56.87% | |
| 70 | ARWRArrowhead Pharmaceuticals, Inc. | 1,009,509 | $5.4B | 56.31% | |
| 71 | CNCEEURConcert Pharmaceuticals, Inc. | 470,058 | $5.3B | 55.35% | |
| 72 | AERIEURAerie Pharmaceuticals, Inc. | 299,356 | $5.3B | 55.24% | |
| 73 | NERVGBPMinerva Neurosciences, Inc. | 508,405 | $5.2B | 54.42% | |
| 74 | —NeuroDerm Ltd. | 305,000 | $5.0B | 51.96% | |
| 75 | —Medgenics, Inc. | 880,539 | $4.9B | 51.24% | |
| 76 | —Syros Pharmaceuticals, Inc. | 204,465 | $3.7B | 38.91% | |
| 77 | CPRXCatalyst Pharmaceuticals, Inc. | 5,122,153 | $3.6B | 38.13% | |
| 78 | MCRB1EURSeres Therapeutics, Inc. | 125,000 | $3.6B | 38.07% | |
| 79 | —Endocyte, Inc. | 1,130,577 | $3.6B | 38.05% | |
| 80 | —Loxo Oncology, Inc. | 137,735 | $3.2B | 33.48% | |
| 81 | —Curis, Inc. | 1,999,303 | $3.1B | 32.70% | |
| 82 | —Ignyta, Inc. | 571,000 | $3.1B | 32.45% | |
| 83 | —Juno Therapeutics, Inc. | 80,000 | $3.1B | 32.24% | |
| 84 | —Trevena, Inc. | 450,000 | $2.8B | 29.72% | |
| 85 | GLYCEURGlycoMimetics, Inc. | 381,235 | $2.8B | 29.06% | |
| 86 | —Nabriva Therapeutics AG | 350,000 | $2.6B | 27.52% | |
| 87 | —Adamas Pharmaceuticals, Inc. | 172,630 | $2.6B | 27.41% | |
| 88 | —Array BioPharma Inc. Notes 3.0% 6/1/2020 | 3,000,000 | $2.5B | 26.67% | |
| 89 | —Osiris Therapeutics, Inc. | 499,193 | $2.5B | 26.64% | |
| 90 | SELBUSDSelecta Biosciences, Inc. | 178,950 | $2.5B | 26.25% | |
| 91 | —Sunesis Pharmaceuticals, Inc. | 4,450,000 | $2.4B | 25.55% | |
| 92 | —Proteon Therapeutics, Inc. | 298,591 | $2.4B | 25.14% | |
| 93 | —Epizyme, Inc. | 232,481 | $2.4B | 24.96% | |
| 94 | —InVivo Therapeutics Holdings Corp. | 400,000 | $2.3B | 24.24% | |
| 95 | —Protalix BioTherapeutics, Inc. Notes 4.5% 9/15/18 | 3,423,000 | $2.3B | 24.11% | |
| 96 | —Stemline Therapeutics, Inc. | 333,497 | $2.3B | 23.67% | |
| 97 | AUPHAurinia Pharmaceuticals Inc. | 711,499 | $2.1B | 22.23% | |
| 98 | AGLEUSDAeglea BioTherapeutics, Inc. | 404,230 | $2.0B | 20.60% | |
| 99 | TREURTrillium Therapeutics Inc. | 211,792 | $1.9B | 19.94% | |
| 100 | —Ophthotech Corporation | 35,649 | $1.8B | 19.07% |
Page 1 of 2Next